HER2 Lung Cancer Explained: Resistance & Emerging Research | Dr. Concannon | Pt 3

Most patients on targeted therapy eventually hear the word "resistance" Here's what's actually happening, and what comes after. In Part 3 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) get into the harder questions: what resistance actually is, the difference between on-target and off-target resistance, how a cancer can transform into a different type entirely, why combination approaches are being studied, and the emerging research, from new pills to cellular therapies, that's moving the field forward. This is Part 3 of 3. Part 1 covers the basics of HER2; Part 2 covers treatment and monitoring. About Dr. Kyle Concannon: Assistant Professor of Medicine-Medical Oncology at the University of Colorado and a thoracic medical oncologist at UCHealth University of Colorado Hospital. Trained as a physician-scientist at MD Anderson, his lab studies why oncogene-driven lung cancers (EGFR, HER2, ALK, ROS1) stop responding to therapy and how to overcome that resistance. He also co-hosts the @crackingcancer podcast. This series is proudly sponsored by Boehringer Ingelheim. YLCI retains full editorial control over content. Educational content, not medical advice. Always talk to your own care team about your specific situation. Chapters 00:00 Welcome and what this final episode covers 00:41 What resistance actually is at the cell level 04:44 What the lab is learning about why therapy stops working 06:33 Patterns of resistance patients should know about 07:24 Why combination approaches are being studied 09:24 Emerging research: new pills, degraders, cellular therapies 11:28 How to stay close to the science and advocate for yourself 13:45 What to hold onto with a new diagnosis #HER2LungCancer #Exon20 #LungCancerResearch 📢 Amplifying the Voices of Young-Onset Lung Cancer Lung cancer is often caught late in young adults because "they're too young." At the Young Lung Cancer Initiative (YLCI), we are changing that narrative. We are a 501(c)(3) nonprofit dedicated to providing support, research, and advocacy for the young-onset community. New here? Hit SUBSCRIBE to help us share these stories and ensure no young person faces this diagnosis alone. 💙 Learn More 🌐 Visit Our Website: https://ylci.org/ 📱 Connect With Us Instagram— @younglungcancer 📧 Contact Us Have questions, ideas, or want to collaborate? Email: [email protected] ⚠️ Disclaimer This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. #YoungLungCancer #LCSM #LungCancerAwareness #CancerSupport #YoungAdultCancer #Nonprofit #PatientAdvocacy #CancerCommunity